Navigation Links
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
Date:11/30/2011

SEATTLE, Nov. 30, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that with its identification of compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR19, GPR20, GPR31 and GPR141 – it has now unlocked over 20 percent of the 77 Class A orphans.  GPCRs represent the premier family of drug targets, with more than 30 percent of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros, which expects to unlock a large percentage of these for drug development, is initially targeting Class A orphan GPCRs.

The four additional orphan receptors unlocked by Omeros are linked to important potential indications. GPR19 has been tied to metastatic melanoma, the most advanced stage of melanoma.  GPR20 and GPR141 are expressed in areas of the body associated with gastrointestinal disorders and respiratory/immunologic disorders, respectively.  GPR31 has been implicated in anxiety disorders, which affect approximately 40 million adults in the United States in a given year.  By identifying compounds that interact selectively with each of these four orphan receptors – as for the other 14 orphan GPCRs that it has previously unlocked – Omeros is uniquely able to provide templates to the pharmaceutical industry for the design of proprietary compounds that interact with these receptors.

"We continue to march through the Class A orphan GPCRs and have initiated compound optimization," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "In parallel, we are executing on our intellectual property strategy to protect each unlocked target through a multipronged approach directed to compound structures, uniquely identified signaling pathways and associated therapeutic indications.  C
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
2. Omeros to Present at Two Upcoming Conferences
3. Omeros to Present at Future Leaders in the Biotech Industry Conference
4. Omeros to Present at Needham Healthcare Conference
5. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
6. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
7. Omeros Secures $40 Million Committed Equity Financing Facility
8. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
9. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Omeros Commences Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... cells, called photoreceptors, could hold the key to stopping ... diseases, Yale School of Medicine researchers report in the ... Several blinding disorders are known to cause ... comparative medicine and ophthalmology at Yale School of Medicine, ...
... , PHOENIX, Nov. 16 NutraCea (OTC: ... research and technology, announced today that Henk Hoogenkamp, a world ... meat processing industries, has agreed to act as an Executive ... results of research and development in various applications to further ...
... , BOSTON, Nov. 16 Hollis-Eden Pharmaceuticals, ... of its ongoing Phase I/II clinical trial with Apoptone® ... cancer or CRPC). Presented at the Molecular ... the AACR, NCI and EORTC, the poster is titled: ...
Cached Biology Technology:Finding a protective mechanism for retinal cells could save sight 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 4
(Date:4/20/2014)... 2014 -- Using corn crop residue to make ethanol ... more greenhouse gases than gasoline, according to a study ... . , The findings by a University of Nebraska-Lincoln ... can be used to meet federal mandates to ramp ... Corn stover -- the stalks, leaves and cobs in ...
(Date:4/18/2014)... researchers have published soil organic carbon sequestration rates. ... organic carbon can be sequestered by simply switching from ... there is a growing body of research with evidence ... cover crops, small grains, and forages may not be ... , "Some studies have shown that both moldboard and ...
(Date:4/18/2014)... team of researchers led by a University of California, ... a $7.5 million Department of Defense grant to uncover ... foundations for the predictable design of light-weight, tough and ... structures from plants and animals, including the mantis shrimp, ... systems have constructed over millions of years and coming ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3
... in the June issue of American Naturalist, Erika J. ... and Michael J. Donoghue (Yale University) explore how leafy, ... "The cactus form is often heralded as a striking ... in plants," write the authors. "A succulent, long-lived photosynthetic ...
... researcher in Washington, D.C., has been working toward tracking ... hepatitis C. , Dr. Maria Sjogren, a retired Army ... in treating liver disease, has enrolled 90 active-duty servicemembers ... Center. The virus, which affects the U.S. military at ...
... Max Planck scientists have identified a new strategy which ... was carried out by Prof. Jonathon Howard and Stefan ... Biology and Genetics in Dresden. The motor protein MCAK ... end of microtubules where it disassembles them. This is ...
Cached Biology News:Researcher studies, treats military with 'silent disease' 2Researcher studies, treats military with 'silent disease' 3Researcher studies, treats military with 'silent disease' 4
... Idaho Technologys R.A.P.I.D. System (Ruggedized Advanced ... real-time, PCR thermocycler designed for field ... environments. In addition to its ruggedness, ... sensitivity and specify as the LightCycler ...
... ES Cell Characterization Kit consists of two ... as well as four ES cell-specific antibodies ... • Stem cells have become the subject ... their therapeutic potential and because they raise ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Note: Evaluated for its amino acid acceptor activity ... acids Ala, Asp, Gly, Ile, Lys, Pro, Thr, ... Preparation Unit Definition: One unit will yield an ... of water (1 cm light path). ...
Biology Products: